Agent for improving cytokine release syndrome, etc.

A technology of cytokines and syndromes, applied in the direction of anti-inflammatory agents, drug combinations, non-central analgesics, etc.

Pending Publication Date: 2020-12-18
TORII PHARMA
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] The current CAR-T cell therapy is mainly limited to blood cancers, and no clear results have been obtained in the case of solid cancers. Therefore, more powerful CAR genes and combination drugs are also being studied

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Agent for improving cytokine release syndrome, etc.
  • Agent for improving cytokine release syndrome, etc.
  • Agent for improving cytokine release syndrome, etc.

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0210] 1. Method

[0211] 1.1 Materials

[0212] 1.1.1 Cells

[0213] Cryopreserved Human PBMC (PBMC): BIOPREDIC

[0214] CD19-CAR-T cells (CAR-T cells) containing CD3 / CD28 signal sequences: provided by the Molecular Therapy Field, Institute of Medical Science, The University of Tokyo

[0215] CD19-expressing K562 cell line (target cell): Provided by the Molecular Therapy Field of the Institute of Medical Sciences, The University of Tokyo

[0216] Human Monocyte (monocyte): BIOPREDIC

[0217] Lenti-X293T cells: Clontech

[0218] 1.1.2 Reagents

[0219] RPMI1640 medium: Thermo fisher (Gibco)

[0220] Fetal bovine serum (FBS): Thermo fisher (Gibco)

[0221] D-PBS(-): Wako Pure Chemical Industries

[0222] Ethylenediaminetetraacetic Acid Disodium Dihydrogen Dihydrate (EDTA): Pure Chemistry

[0223] Bovine Serum Albumin (BSA): SIGMA

[0224] Dimethyl sulfoxide (DMSO): SIGMA

[0225] Penicillin-Streptomycin-Glutamine: Thermo fisher

[0226] 2-Mercaptoethanol: SIGMA

[...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

To provide a drug for cytokine release syndrome, autoimmune-disease-related side effects, macrophage activation syndrome, hemophagocytic lymphohistiocytosis, or Langerhans cell histiocytosis. A drug for at least one selected from the group consisting of cytokine release syndrome, autoimmune-disease-related side effects, macrophage activation syndrome, hemophagocytic lymphohistiocytosis, and Langerhans cell histiocytosis, the drug containing a compound represented by formula I or a pharmacologically acceptable salt thereof.

Description

technical field [0001] The present invention relates to agents for preventing, treating or improving cytokine release syndrome, side effects associated with autoimmune diseases, macrophage activation syndrome, hemophagocytic lymphohistiocytosis or Langerhans cell histiocytosis . Background technique [0002] In recent years, T cell (CAR-T cell) therapy expressing chimeric antigen receptor (CAR) and T cell (TCR-T cell) gene-modified T cell receptor (TCR) have been tried to treat cancer. T-cell) therapy. In addition, from the viewpoint of activation of the immune system occurring in vivo, such cancer therapy by T cell activation has commonality with cancer therapy by immune checkpoint inhibitors. Cell therapy methods such as CAR-T cells are autologous T cell therapy methods in which T cells collected from patients are genetically modified to express CARs with target capabilities and specific TCRs, and then returned to the body. T cells expressing CAR and the like not only k...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/495A61P29/00A61P43/00
CPCA61P29/00A61P43/00A61K31/495A61P37/00A61P37/06
Inventor 渡部良广田原善夫铃木启介三村孝之大前沙织
Owner TORII PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap